If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
182
results.
Updated on
15/11/2026 [07:06:00]
Results 100 to 125 of 182
Absstract of: US20260327704A1
This invention provides gene expression profiles useful for diagnosing atrial fibrillation in ischemic stroke and for distinguishing atrial fibrillation in ischemic stroke from arterial (large vessel) stroke or embolic stroke of undetermined source (ESUS).
Absstract of: US20260325655A1
The present disclosure provides compounds of the formulae herein (e.g., Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which bind and/or effect degradation of an RNA target. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
Absstract of: US20260327295A1
The present invention relates to single-domain antibodies (sdAbs) binding C-reactive protein (CRP). In particular, the invention relates to sdAbs that bind CRP within a specific range of an on-rate constant and off-rate constant. The sdAbs of the present invention can associate and dissociate with CRP in a continuous manner. The invention further relates to nucleic acids encoding anti-CRP sdAbs, methods for detecting CRP, methods of treatment and diagnosis making use of the anti-CRP sdAbs, methods for monitoring CRP levels and apparatuses comprising the anti-CRP sdAbs.
Absstract of: US20260327296A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Absstract of: US20260327702A1
0000 The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
Absstract of: US20260328782A1
0000 The present disclosure provides methods for monitoring inflammation in ALS and other related diseases. Therapeutic interventions based on the results of monitoring methods are also provided.
Absstract of: US20260328758A1
Provided is a method for detecting target substances. The method includes a) introducing a sample containing target substances onto a substrate, b) allowing detection probes conjugated with docking strands to specifically bind to the target substances, c) introducing one or more separate strands capable of complementary binding to the docking strands into the docking strands, either the docking strands or the separate strands, or both, are labeled with at least one donor fluorescent substance and at least one acceptor fluorescent substance, and d) measuring fluorescence signals generated by the FRET between the donor fluorescent substance and the acceptor fluorescent substance to identify the target substances.
Absstract of: AU2025258452A1
Provided herein are an antibody or antigen binding fragment that specifically recognizes and/or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.
Absstract of: AU2026210766A1
The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease. ul u l
Absstract of: US20260327282A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Absstract of: US20260328775A1
0000 Provided is a method of efficiently isolating and detecting an antigen molecule from an antigen-antibody complex in a biological sample. Provided is a method of isolating an antigen molecule from a liquid sample comprising an antigen-antibody complex, the method including: a binding step of binding the antibody molecule in the antigen-antibody complex to an antibody-binding protein by applying the liquid sample to a column on which the antigen-binding protein is immobilized; and an elution step of eluting an elution liquid comprising the antigen molecule by applying a buffer liquid to the column to dissociate the antigen molecule in the antigen-antibody complex from the antibody molecule, wherein the buffer liquid is applied to the column while the pH of the buffer liquid decreases in a continuous or stepwise manner in the elution step.
Absstract of: US20260327196A1
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
Absstract of: US20260327309A1
0000 The present disclosure relates to combination therapies comprising immune checkpoint inhibitors and antibodies directed to neurological biomarkers, compositions comprising immune checkpoint inhibitors and antibodies directed to neurological biomarkers, and methods of treatment using such combination therapies and/or compositions.
Absstract of: US20260328783A1
The present disclosure relates to a biomarker composition for diagnosis of a degenerative brain disease, and more particularly, in an attempt to distinguish between normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients, provides a biomarker composition that distinguishes between the normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients by measuring levels of amyloid beta 40 (Aβ40), amyloid beta 42 (Aβ42), brain-derived neurotrophic factor (BDNF), Tau, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), peptidyl-prolyl isomerase (PIN1), collapsing response mediator protein-2 (CRMP2), phospho-Tau231, and olfactory marker protein (OMP) as biomarkers in the blood to identify correlation thereof.
Absstract of: US20260325471A1
Disclosed are methods, systems, compositions, and kits for diagnosing, staging, monitoring, and treating conditions associated with bioenergetic insufficiency in a subject or biological system. The disclosure is grounded in the Unified Theory of Bioenergetic Sufficiency (UTBS), which defines cellular health based on maintaining a Metabolic Sufficiency Ratio (M), the ratio of effective energy generation rate (E) to total energy requirement rate (R), above a critical threshold (M=E/R >M_crit). As well as, Metabolic-Epigenetic-Redox Immune Therapy (MERIT), a new therapeutic class of pharmacological, treat-to-target ketone body therapies for diseases characterized by metabolic, redox, epigenetic, or immune dysregulation.
Absstract of: WO2026221738A1
The present disclosure provides genes and genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy and methods of determining if a subject is responsive or non-responsive to Sigma-1 receptor therapy. The methods can be used to optimize treatment for subjects in need of Sigma-1 receptor therapy. Based on the predicted responsiveness of a subject to the therapy, personalized treatment can be provided to each subject.
Absstract of: WO2026222088A1
The present disclosure describes a method of isolating neuronal-derived extracellular vesicles (NEVs) and obtaining an enriched population of NEVs. The enriched population of NEVs can be used for detecting neurodegenerative diseases. As described herein, ICAM-5 is a specific neuronal marker present on NEVs and offers a highly specific method for NEVs enrichment. Various implementations of the present disclosure provide enhanced sensitivity and accuracy of biomarker detection for neurodegenerative diseases. The high CNS specificity associated with ICAM-5, compared to other reported markers, can significantly improve diagnostic modalities by providing more reliable information that accurately reflects the molecular changes in the brain, leading to earlier and more precise diagnoses.
Absstract of: WO2026222207A1
Disclosed herein are highly sensitive NULISA immunoassays that utilize a capture/release mechanism to reduce non-specific binding and achieve detection with attomolar-level sensitivity to detect multiple forms of phosphorylated brain-derived Tau and total Tau in blood. Kits that can be used for carrying out these highly sensitive immunoassays are also disclosed herein.
Absstract of: US20260325651A1
0000 The disclosure relates to lipase modulators, compositions comprising such modulators, and methods of using the same to regulate lipid metabolism, efferocytosis, and/or macrophage function. In certain aspects, the disclosure provides compositions and methods for modulating intracellular lipase activity, lipolysis, inflammatory signaling, membrane remodeling, and/or pro-resolving macrophage polarization, including for treating conditions associated with dysregulated lipid metabolism, impaired efferocytosis, and/or impaired macrophage function. The disclosure also provides in vitro methods for identifying candidate agents that increase macrophage efferocytosis, enhance lipase-associated signaling or activity, increase membrane fluidity, increase receptor clustering or receptor polarization, or promote a pro-resolving macrophage phenotype.
Absstract of: US20260325476A1
0000 Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
Absstract of: US2022082552A1
0001 Methods and uses of compositions (e.g. comprising one or more microbial strains) are disclosed.
Absstract of: WO2025062119A2
The invention relates to a compound of formula I, wherein: A, B, R1, R2, L1, m and n are as defined in the specification, or a salt or solvate thereof, which compounds are useful for forming Raman-tagged bioconjugates with a biomarker and/or biomolecule and are detectable with Raman spectroscopy
Absstract of: EP4826385A1
The present invention relates to method of determining risk of an inflammatory condition, and/or risk of progression of an inflammatory condition, as well as to compounds for use in these methods.
Absstract of: CN122953248A
本公开属于生物医药领域，具体涉及靶向IL‑6R和α4β7的双特异性抗体及其应用。本公开的靶向IL‑6R和α4β7的双特异性抗体对IL‑6R和/或α4β7具有较好的亲和力和/或生物学活性，可用于检测IL‑6R和/或α4β7、诊断或防治与IL‑6R和/或α4β7相关的疾病或病症。
Nº publicación: CN122937868A 20/10/2026
Applicant:
桂林电子科技大学
Absstract of: CN122937868A
本发明公开一种磁性免疫富集微流控芯片及其在电致发光下对p‑Tau217的检测方法，属于微流控生物检测领域。芯片包括可拆合的主体板和底板，主体板设有样品、检测探针及洗涤液/共反应剂进样口，三路流道汇合后经蛇形通道与富集混合反应腔连通。反应腔下方设可移动磁体，用于截留、原位洗涤和释放携带夹心免疫复合物的SiO2@Fe3O4磁珠。富集后的磁珠复合物经出口导入三电极电化学发光检测池进行信号采集。本发明利用蛇形流道、回流抑制结构、圆角过渡及可移动磁场，减少磁珠沉积和非特异性背景，适用于离体血清或血浆样本中p‑Tau217的体外定量检测。
BOPI
Electronic site
